Linvoseltamab, is an experimental anti-cancer medication intended for the treatment of people with relapsed and refractory multiple myeloma.[1][2] Linvoseltamab is a bispecific monoclonal antibody that targets CD3 and BCMA (TNFRSF17).[1]

Society and culture

In February 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Lynozyfic, intended for the treatment of people with relapsed and refractory multiple myeloma who have received at least three prior therapies.[1] The applicant for this medicinal product is Regeneron Ireland DAC.[1]

Names

Linvoseltamab is the international nonproprietary name.[3]

References

  1. ^ a b c d "Lynozyfic EPAR". European Medicines Agency (EMA). 27 February 2025. Retrieved 6 March 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. ^ Avigan ZM, Rattu MA, Richter J (February 2025). "An evaluation of linvoseltamab for treatment of relapsed/refractory multiple myeloma". Expert Opinion on Biological Therapy: 1–8. doi:10.1080/14712598.2025.2465825. PMID 39923122.
  3. ^ World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88". WHO Drug Information. 36 (3). hdl:10665/363551.


Allikas: https://en.wikipedia.org/wiki/Linvoseltamab
No tags for this post.